Published in J Allergy Clin Immunol on February 09, 2007
Molecular approach to allergy diagnosis and therapy. Yonsei Med J (2014) 1.01
Mechanisms underlying allergy vaccination with recombinant hypoallergenic allergen derivatives. Vaccine (2011) 1.01
Food allergy: recent advances in pathophysiology and treatment. Allergy Asthma Immunol Res (2009) 0.90
Recombinant allergens: the present and the future. Hum Vaccin Immunother (2012) 0.83
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature (2011) 11.44
Revised international prognostic scoring system for myelodysplastic syndromes. Blood (2012) 8.12
New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood (2007) 5.80
Mast Cells, Mastocytosis, and Related Disorders. N Engl J Med (2015) 3.90
New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol (2012) 3.88
Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med (2004) 3.83
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood (2007) 3.59
Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol (2006) 2.80
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A (2007) 2.51
Allergic disease and sensitization in Steiner school children. J Allergy Clin Immunol (2005) 2.44
Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol (2011) 2.29
Stat5 tetramer formation is associated with leukemogenesis. Cancer Cell (2005) 2.26
Atopic sensitization and the international variation of asthma symptom prevalence in children. Am J Respir Crit Care Med (2007) 2.21
Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis. Cell (2011) 2.11
High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood (2011) 2.08
Varying allergen composition and content affects the in vivo allergenic activity of commercial Dermatophagoides pteronyssinus extracts. Int Arch Allergy Immunol (2012) 2.05
Leukemic challenge unmasks a requirement for PI3Kdelta in NK cell-mediated tumor surveillance. Blood (2008) 2.04
Development of Churg-Strauss syndrome with controlled asthma during omalizumab treatment. J Allergy Clin Immunol (2008) 2.03
Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. J Clin Oncol (2011) 2.02
Mast cell activation syndrome: Proposed diagnostic criteria. J Allergy Clin Immunol (2010) 1.98
Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol (2012) 1.88
Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol (2007) 1.87
Prenatal farm exposure is related to the expression of receptors of the innate immunity and to atopic sensitization in school-age children. J Allergy Clin Immunol (2006) 1.84
Phl p 5 resorption in human oral mucosa leads to dose-dependent and time-dependent allergen binding by oral mucosal Langerhans cells, attenuates their maturation, and enhances their migratory and TGF-beta1 and IL-10-producing properties. J Allergy Clin Immunol (2010) 1.80
Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression. J Exp Med (2009) 1.73
Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. Leuk Res (2004) 1.71
Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol (2005) 1.68
PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. Nat Med (2012) 1.67
Microarrayed allergen molecules: diagnostic gatekeepers for allergy treatment. FASEB J (2002) 1.66
Mastocytosis: state of the art. Pathobiology (2007) 1.64
Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol (2008) 1.64
Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol (2011) 1.63
The basophil-specific ectoenzyme E-NPP3 (CD203c) as a marker for cell activation and allergy diagnosis. Int Arch Allergy Immunol (2004) 1.63
Risk assessment in anaphylaxis: current and future approaches. J Allergy Clin Immunol (2007) 1.57
Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol (2002) 1.54
Evaluation of IgE antibodies to recombinant peanut allergens in patients with reported reactions to peanut. Int Arch Allergy Immunol (2011) 1.54
Severe peripheral arterial disease during nilotinib therapy. J Natl Cancer Inst (2011) 1.52
High sensitivity of CAP-FEIA rVes v 5 and rVes v 1 for diagnosis of Vespula venom allergy. J Allergy Clin Immunol (2012) 1.52
A WAO - ARIA - GA²LEN consensus document on molecular-based allergy diagnostics. World Allergy Organ J (2013) 1.51
Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML. Oncotarget (2012) 1.50
Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias. Blood (2006) 1.50
Low sensitivity of commercially available rApi m 1 for diagnosis of honeybee venom allergy. J Allergy Clin Immunol (2011) 1.49
Recombinant allergens promote expression of CD203c on basophils in sensitized individuals. J Allergy Clin Immunol (2002) 1.47
From allergen genes to allergy vaccines. Annu Rev Immunol (2010) 1.46
High dose intermittent ARA-C (HiDAC) for consolidation of patients with de novo AML: a single center experience. Leuk Res (2005) 1.44
Wheat allergy in children evaluated with challenge and IgE antibodies to wheat components. Pediatr Allergy Immunol (2015) 1.44
Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD). J Pathol (2010) 1.44
Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category. Leuk Lymphoma (2006) 1.42
Different modes of IgE binding to CD23 revealed with major birch allergen, Bet v 1-specific monoclonal IgE. Immunol Cell Biol (2012) 1.41
Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica (2009) 1.40
Evaluation of biologic activity of tryptase secreted from blast cells in acute myeloid leukemia. Leuk Lymphoma (2006) 1.39
[Aleukemic mast cell leukemia (formerly: "malignant mastocytosis"): an extremely rare form of leukemia. A case report and simultaneously a contribution to revised classification of mastocytosis]. Wien Klin Wochenschr (2002) 1.38
Peanut allergy: Clinical and immunologic differences among patients from 3 different geographic regions. J Allergy Clin Immunol (2010) 1.37
High-affinity IgE recognition of a conformational epitope of the major respiratory allergen Phl p 2 as revealed by X-ray crystallography. J Immunol (2009) 1.37
A Th17- and Th2-skewed cytokine profile in cystic fibrosis lungs represents a potential risk factor for Pseudomonas aeruginosa infection. Am J Respir Crit Care Med (2013) 1.36
The melanocyte-specific isoform of the microphthalmia transcription factor affects the phenotype of human melanoma. Cancer Res (2002) 1.35
Comprehensive mutational profiling in advanced systemic mastocytosis. Blood (2013) 1.35
Cat IgA, representative of new carbohydrate cross-reactive allergens. J Allergy Clin Immunol (2007) 1.34
Residential proximity fine particles related to allergic sensitisation and asthma in primary school children. Respir Med (2007) 1.32
Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily. Haematologica (2010) 1.27
Not all farming environments protect against the development of asthma and wheeze in children. J Allergy Clin Immunol (2007) 1.27
Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis. Mod Pathol (2010) 1.25
Traffic-related air pollution and development of allergic sensitization in children during the first 8 years of life. J Allergy Clin Immunol (2011) 1.21
Identification of CD13, CD107a, and CD164 as novel basophil-activation markers and dissection of two response patterns in time kinetics of IgE-dependent upregulation. Cell Res (2005) 1.21
Diagnostic and subdiagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: Monoclonal mast cell activation syndrome. Int Arch Allergy Immunol (2006) 1.21
Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). Biol Blood Marrow Transplant (2008) 1.19
Identification of heme oxygenase-1 as a novel BCR/ABL-dependent survival factor in chronic myeloid leukemia. Cancer Res (2004) 1.18
Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts. Int Arch Allergy Immunol (2002) 1.17
Detection of molecular targets on the surface of CD34+/CD38-- stem cells in various myeloid malignancies. Leuk Lymphoma (2006) 1.16
Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood (2012) 1.16
Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives. Expert Rev Hematol (2010) 1.16
Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade. Blood (2008) 1.16
Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: the diagnostic interface. Leuk Res (2007) 1.16
A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS. J Allergy Clin Immunol (2011) 1.15
Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol (2011) 1.15
Different IgE reactivity profiles in birch pollen-sensitive patients from six European populations revealed by recombinant allergens: an imprint of local sensitization. Int Arch Allergy Immunol (2002) 1.15
Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens. J Immunol (2008) 1.15
Morphologic and immunophenotypic properties of neoplastic cells in a case of mast cell sarcoma. Am J Surg Pathol (2003) 1.14
Identification of Der p 23, a peritrophin-like protein, as a new major Dermatophagoides pteronyssinus allergen associated with the peritrophic matrix of mite fecal pellets. J Immunol (2013) 1.14